CN113164565A - 包含外源性活化环的梭菌神经毒素 - Google Patents

包含外源性活化环的梭菌神经毒素 Download PDF

Info

Publication number
CN113164565A
CN113164565A CN201980078275.8A CN201980078275A CN113164565A CN 113164565 A CN113164565 A CN 113164565A CN 201980078275 A CN201980078275 A CN 201980078275A CN 113164565 A CN113164565 A CN 113164565A
Authority
CN
China
Prior art keywords
seq
clostridial neurotoxin
bont
engineered
activation loop
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980078275.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·库平斯基
L·洛夫洛克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Biopharm Ltd
Original Assignee
Ipsen Biopharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Biopharm Ltd filed Critical Ipsen Biopharm Ltd
Publication of CN113164565A publication Critical patent/CN113164565A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893Botulinum neurotoxin (3.4.24.69)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6408Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/06Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21009Enteropeptidase (3.4.21.9), i.e. enterokinase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24Metalloendopeptidases (3.4.24)
    • C12Y304/24069Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980078275.8A 2018-09-28 2019-09-27 包含外源性活化环的梭菌神经毒素 Pending CN113164565A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1815817.0 2018-09-28
GBGB1815817.0A GB201815817D0 (en) 2018-09-28 2018-09-28 Clostridial neurotoxins comprising and exogenous activation loop
PCT/GB2019/052732 WO2020065336A1 (en) 2018-09-28 2019-09-27 Clostridial neurotoxins comprising an exogenous activation loop

Publications (1)

Publication Number Publication Date
CN113164565A true CN113164565A (zh) 2021-07-23

Family

ID=64108972

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980078275.8A Pending CN113164565A (zh) 2018-09-28 2019-09-27 包含外源性活化环的梭菌神经毒素

Country Status (16)

Country Link
US (1) US12589139B2 (https=)
EP (1) EP3856232A1 (https=)
JP (2) JP7511549B2 (https=)
KR (1) KR20210068476A (https=)
CN (1) CN113164565A (https=)
AU (1) AU2019348732C1 (https=)
BR (1) BR112021005017A2 (https=)
CA (1) CA3111962A1 (https=)
EA (1) EA202190889A1 (https=)
GB (1) GB201815817D0 (https=)
IL (1) IL281814A (https=)
MX (1) MX2021003261A (https=)
SG (1) SG11202102323TA (https=)
TW (2) TW202517790A (https=)
UA (1) UA130362C2 (https=)
WO (1) WO2020065336A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116813727A (zh) * 2023-06-08 2023-09-29 深圳德进生物科技有限公司 一种a型肉毒毒素的制备方法及其应用
WO2024046404A1 (zh) * 2022-09-01 2024-03-07 上海蓝晶生物科技有限公司 一种重组肉毒杆菌毒素及其制备方法
CN118126143A (zh) * 2024-03-14 2024-06-04 河北平朴生物科技合伙企业(有限合伙) 一种a型肉毒毒素的突变体及其应用
CN119859174A (zh) * 2025-01-13 2025-04-22 乐普健糖药业(重庆)有限公司 重组肉毒毒素及其制备方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
GB201815817D0 (en) * 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB202103372D0 (en) 2021-03-11 2021-04-28 Ipsen Biopharm Ltd Modified clostridial neurotoxins
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
WO2022208091A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
JP7659653B2 (ja) 2021-03-30 2025-04-09 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
GB202213479D0 (en) 2022-09-14 2022-10-26 Ipsen Biopharm Ltd Cell-free clostridial neurotoxin assays
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) * 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
GB202320108D0 (en) 2023-12-28 2024-02-14 Ipsen Biopharm Ltd Biosensor
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010020811A1 (en) * 2008-08-21 2010-02-25 Syntaxin Limited Non-cytotoxic fusion proteins comprising egf muteins
CN102307571A (zh) * 2008-12-10 2012-01-04 阿勒根公司 梭菌毒素药物组合物
EP1999142B1 (en) * 2006-03-15 2013-07-10 Allergan, Inc. Multivalent clostridial toxins
WO2016110662A1 (en) * 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
AU3658093A (en) 1992-02-10 1993-09-03 Seragen, Inc. Desensitization to specific allergens
GB9305735D0 (en) 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
DK1084146T3 (da) 1998-05-13 2003-02-03 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Hybridprotein til inhibering af degranuleringen af mastocyter og anvendelse deraf
ES2205849T3 (es) 1998-07-22 2004-05-01 Osprey Pharmaceuticals Limited Conjugados para tratar alteraciones inflamatorias y asociadas con daños tisulares.
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
WO2000039310A1 (en) * 1998-12-29 2000-07-06 The University Of Georgia Research Foundation, Inc. Rubredoxin fusion proteins, protein expression system and methods
US6776990B2 (en) 1999-04-08 2004-08-17 Allergan, Inc. Methods and compositions for the treatment of pancreatitis
US6358697B2 (en) 1999-04-21 2002-03-19 Children's Hospital Medical Center Intracellular pharmaceutical targeting
HK1046020B (en) 1999-08-25 2007-05-11 Allergan, Inc. Activatable recombinant neurotoxins
GB9922554D0 (en) 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US6903187B1 (en) 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7273722B2 (en) 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
PL1830872T3 (pl) 2004-12-01 2011-09-30 Sec Dep For Health Białka fuzyjne
DE102005019302A1 (de) 2005-04-26 2006-11-16 Toxogen Gmbh Carrier zum Targeting von Nervenzellen
ES2369558T3 (es) 2005-09-19 2011-12-01 Allergan, Inc. Toxinas clostridiales y toxinas clostridiales activables.
EP1931379B1 (en) * 2005-10-07 2013-05-29 Health Protection Agency Proteins with improved solubility and methods for producing and using same
EP1834962A1 (de) 2006-03-15 2007-09-19 Biotecon Therapeutics GmbH PEGyliertes mutiertes Clostridium botulinum Toxin
AU2007272515B2 (en) 2006-07-11 2013-09-26 Allergan, Inc. Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells
JP2009543558A (ja) 2006-07-11 2009-12-10 アラーガン、インコーポレイテッド 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素
JP5799397B2 (ja) * 2008-06-12 2015-10-28 イプセン・バイオイノベーション・リミテッドIpsen Bioinnovation Limited 癌の抑制
GB0903006D0 (en) 2009-02-23 2009-04-08 Syntaxin Ltd Modified non-cytotoxic proteases
CA2758274C (en) 2009-04-14 2018-04-10 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
CZ2010374A3 (cs) * 2010-05-13 2011-06-29 Zentiva, K.S. Rekombinantní produkce teriparatidu v bakteriích Escherichia coli
US8853360B2 (en) 2010-06-23 2014-10-07 Wisconsin Alumni Research Foundation Engineered botulinum neurotoxin C1 with selective substrate specificity
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2013091895A1 (en) 2011-12-23 2013-06-27 Merz Pharma Gmbh & Co. Kgaa Novel method for the manufacturing of di-chain proteins for use in humans
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
WO2014079495A1 (en) 2012-11-21 2014-05-30 Syntaxin Limited Methods for the manufacture of proteolytically processed polypeptides
GB201407525D0 (en) 2014-04-29 2014-06-11 Syntaxin Ltd Manufacture of recombinant clostridium botulinum neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
US11242515B2 (en) 2016-05-16 2022-02-08 President And Fellows Of Harvard College Method for purification and activation of botulinum neurotoxin
EP3481852B1 (en) * 2016-07-08 2022-12-07 Children's Medical Center Corporation A novel botulinum neurotoxin and its derivatives
WO2019152380A1 (en) 2018-01-30 2019-08-08 Children's Medical Center Corporation Production of botulinum neurotoxins using bacillus systems
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1999142B1 (en) * 2006-03-15 2013-07-10 Allergan, Inc. Multivalent clostridial toxins
WO2010020811A1 (en) * 2008-08-21 2010-02-25 Syntaxin Limited Non-cytotoxic fusion proteins comprising egf muteins
CN102307571A (zh) * 2008-12-10 2012-01-04 阿勒根公司 梭菌毒素药物组合物
WO2016110662A1 (en) * 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Cationic neurotoxins
US20180141982A1 (en) * 2015-01-09 2018-05-24 Ipsen Bioinnovation Limited Cationic neurotoxins

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024046404A1 (zh) * 2022-09-01 2024-03-07 上海蓝晶生物科技有限公司 一种重组肉毒杆菌毒素及其制备方法
CN116813727A (zh) * 2023-06-08 2023-09-29 深圳德进生物科技有限公司 一种a型肉毒毒素的制备方法及其应用
CN118126143A (zh) * 2024-03-14 2024-06-04 河北平朴生物科技合伙企业(有限合伙) 一种a型肉毒毒素的突变体及其应用
CN118126143B (zh) * 2024-03-14 2025-06-24 河北平朴生物科技合伙企业(有限合伙) 一种a型肉毒毒素的突变体及其应用
CN119859174A (zh) * 2025-01-13 2025-04-22 乐普健糖药业(重庆)有限公司 重组肉毒毒素及其制备方法
CN119859174B (zh) * 2025-01-13 2026-03-20 乐普健糖药业(重庆)有限公司 重组肉毒毒素及其制备方法

Also Published As

Publication number Publication date
JP2022512573A (ja) 2022-02-07
SG11202102323TA (en) 2021-04-29
GB201815817D0 (en) 2018-11-14
JP2024012421A (ja) 2024-01-30
WO2020065336A1 (en) 2020-04-02
KR20210068476A (ko) 2021-06-09
EA202190889A1 (ru) 2021-11-10
TW202027782A (zh) 2020-08-01
BR112021005017A2 (pt) 2021-06-08
AU2019348732B2 (en) 2024-02-15
EP3856232A1 (en) 2021-08-04
JP7511549B2 (ja) 2024-07-05
US20220211823A1 (en) 2022-07-07
TW202517790A (zh) 2025-05-01
AU2019348732A1 (en) 2021-04-15
UA130362C2 (uk) 2026-02-04
JP7819168B2 (ja) 2026-02-24
MX2021003261A (es) 2021-05-12
AU2019348732C1 (en) 2024-08-29
TWI869353B (zh) 2025-01-11
CA3111962A1 (en) 2020-04-02
IL281814A (en) 2021-05-31
US12589139B2 (en) 2026-03-31

Similar Documents

Publication Publication Date Title
JP7819168B2 (ja) 外因性活性化ループを含むクロストリジウム神経毒
US10744190B2 (en) Method for suppressing spasmodic torticollis
EP3242884B1 (en) Cationic neurotoxins
JP2012518403A5 (https=)
US20240327472A1 (en) Modified clostridial neurotoxins
US20240175001A1 (en) Clostridial Neurotoxins Comprising an Exogenous Activation Loop
EP4594341A1 (en) Clostridial neurotoxins comprising an activating exogenous protease cleavage site
HK40058209A (en) Clostridial neurotoxins comprising an exogenous activation loop
AU2023351418A1 (en) Clostridial neurotoxins comprising an activating endosomal protease cleavage site
EA047022B1 (ru) Клостридиальные нейротоксины, содержащие экзогенную петлю активации
HK40099692A (zh) 包含外源性活化环的梭菌神经毒素

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40058209

Country of ref document: HK